pharma segment seem uphold revenu growth
maintain rate hold tp
deriv estim base forward price-to-earnings ep
expect top line growth
base estim number factor continu
rapid growth pulmonari hypertens franchis continu
strong perform pharma segment consum
medic devic segment continu improv growth
strong uptak drazalex emea apac
current face litig babi powder
product led recent declin stock price
might result declin stock perform growth
maintain target price top-lin
revenu growth per previou report
viewpoint unchang upsid
potenti increas due downfal
pharmaceut segment continu double-digit growth
report doubl digit top-lin revenu growth consecut
quarter provid great finish also record
special item charg quarter relat tax
legisl record increas oper expens
adjust ep quarter beat
estim
met consensu revenu beat
estim adjust ep beat estim
mn except ep crispidea namejohnson johnsontickerjnjstock ratingholdunchangedindustri viewoverweightpositivepric feb week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideashej johnson johnson| februari
incom statement
strateg partnership collabor licens
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
total revenu compar
total increas y/i
oper sale result increas posit
impact currenc exclud net impact
acquisit divestitur oper basi
world-wide sale increas
net loss quarter compar
decreas mainli due increas
cost tax provis record
ep basi
 food drug administr fda approv juluca
rilpivirin dolutegravir first complet single-pil
two-drug regimen treatment human
fda approv mg once-daili dose xarelto
rivaroxaban reduc continu risk recurr
venou thromboembol complet least six
month initi anticoagul therapi
actelion acquisit pulmonari hypertens
strong start oncolog darzalex grew
surpass sale
darzalex continu increas market share line two
three experienc market growth line four
complet acquisit licens
variou size innov deal made new
guidanc revenu expect
oper revenu expect
rang adjust ep expect
rang expect ep
growth y/i
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date feb last split factor new per last split date jun inform johnson johnson| februari
incom statement
strateg partnership collabor licens
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
incom statement item month end month end month end month end month end month end month end month end month end month end month end revenu total- total revenu gross selling/general/admin expens research depreciation/amortization- interest expens incom net operating- unusu expens incom oper expens total- total oper oper interest incom expens net non-operating- loss sale assets- net- incom incom minor interest- equiti affiliates- net incom extra account change- discontinu operations- extraordinari item- net prefer dividends- incom avail common excl extra incom avail common incl extra basic weight averag shares- basic ep exclud extraordinari items- basic ep includ extraordinari items- dilut adjustment- dilut weight averag dilut ep exclud extraordinari dilut ep includ extraordinari items- dividend per share common stock primari gross dividend common stock- net incom stock base comp expense- basic ep stock base comp expsense- dilut ep stock base comp expense- depreci supplemental- total special items- normal incom taxes- effect special item incom taxes- incom tax ex impact special items- normal incom taxes- normal incom avail common- basic normal eps- dilut normal actual annual estim annual actual quarterli johnson johnson| februari
 short term short term account receiv trade receiv other- total receiv total prepaid current asset total- total current property/plant/equip total goodwil intang long term investments- long term asset total account accru note payable/short term debt- current port lt debt/capit current liabil total current long term capit leas obligations- total long term total defer incom minor interest- liabil total redeem prefer stock total- prefer stock non redeem net- common stock addit paid-in capital- retain earn accumul treasuri stock equiti total total liabil sharehold share out common stock primari issue- total common share actual annual actual quarterli balanc sheet item johnson johnson| februari
cash equival end
free cash flow avail paid dividend
month end month end month end month end month end month end month end month end income/start work oper invest item invest dividend retir stock retir debt financ exchang chang interest paid tax paid total revenu
compar
y/i
cog quarter
compar
gross margin
quarter decreas
compar
 expens
compar
johnson johnson report doubl digit top-lin revenu growth
consecut quarter provid great finish pharmaceut segment
continu double-digit growth also record special item chare
quarter relat tax legisl experienc increas
oper expens adjust ep quarter
beat estim
total revenu compar
total increas y/i oper sale result increas
posit impact currenc exclud net impact acquisit
divestitur oper basi world-wide sale increas
cog quarter compar
increas y/i increas mainli due higher amort
expens charg inventori step-up relat recent acquisit
partial off-set favor currenc impact product mix gross margin
quarter decreas compar
sg quarter compar
increas increas primarili due invest spend
segment advanc pipelin
 expens compar
increas y/i increas primarili due increas
invest spend segment advanc
process expens quarter
ebit compar decreas
primarili attribut increas oper expens
increas revenu oper margin quarter compar
record special item charg incom tax associ
recent enact tax legisl
net loss quarter compar
decreas mainli due increas cost tax provis
record ep basi
revenu region quarter grew compar
revenu grew oper well
net loss quarter
compar
decreas
mainli due increas
cost tax provis
record
ep
basi
revenu includ europ western hemispher exclud
 asia-pacif africa increas quarter
compar revenu increas y/i
revenu region
quarter grew
compar
oper well
europ revenu
compar
europ
revenu grew
report basi
europ revenu compar europ
revenu grew report basi oper
western hemispher exclud revenu compar
increas report basi
asia-pacif africa revenu quarter compar
asia-pacif revenu grew report basi
total revenu compar
increas y/i oper result increas posit impact
currenc exclud net impact acquisit divestitur
oper basi world-wide sale increas
cog compar increas
y/i increas due amort intang asset
inventori step-up charg relat recent acquisit gross margin
decreas compar
sg compar increas
y/i increas due invest made launch new
revenu region
grew
compar
oper well
 expens compar
increas y/i increas due collabor agreement
idorsia spin actelion legend biotech regard excit new
therapi develop
net incom
compar
decreas mainli
due increas cost
tax provis
record
ep
basi
asia-pacif africa
revenu
grew report
basi
ebit compar decreas
y/i decreas primarili attribut higher percentag
increas oper expens increas revenu oper
margin compar
net incom compar
decreas mainli due increas cost tax provis
record ep basi
revenu region grew compar
revenu grew oper well
revenu includ europ western hemispher exclud
 asia-pacif africa increas
compar revenu increas y/i
europ revenu compar
europ revenu grew report basi oper
western hemispher exclud revenu
compar increas report basi
asia-pacif africa revenu compar
asia-pacif revenu grew report basi
divid major segment consum segment
world-wide consum sale repres increas
oper increas
posit currenc impact growth driven continu
geograph expans new product strong e-commerc growth
world-wide consum sale repres increas
oper increas posit
currenc impact world-wide oper result exclud net impact
acquisit divestitur neg impact declin babi
oral busi mostli off-set growth over-the-count
product includ tylenol analges upper respiratori product
repres increas
repres increas
oper
increas
decreas
reas
 consum segment sale decreas
intern consum segment sale increas
includ oper growth posit currenc impact
 consum segment sale increas
intern consum segment sale increas includ
oper growth posit currenc impact
babi revenu
quarter declin
y/i report
compar
beauti revenu
quarter grew
report
oper y/i
compar
revenu oral
quarter
declin y/i
compar
babi revenu quarter declin y/i report
compar domest babi sale
flat intern babi declin y/i
competit pressur partial off-set lap prior year india
demonet aveeno babi geograph expans aspac
beauti revenu quarter grew report
oper y/i compar domest
beauti revenu quarter grew y/i
beauti revenu grew y/i
growth primarili driven dr ci labo ogx maui moistur share gain
geograph expans e-commerc growth neutrogena aveeno
new product partial off-set increas trade promot suncar
product brazil
revenu oral quarter declin y/i
compar domest revenu oral
declin y/i intern revenu increas y/i
declin due divestitur competit pressur latin america
weak emea primarili due categori slowdown lap
inventori build support trade/media promot event partial
off-set strength aspac due new product launch
over-the-counter revenu quarter increas report
oper y/i compar domest
revenu over-the-counter quarter declin y/i
revenu grew y/i
growth due strength upper respiratori asia pacif primarili due
tylenol benadryl outsid sale increas due rhinocort
acquisit partial off-set stock relat prior retail
inventori reduct tylenol suppli disrupt due hurrican maria
revenu women quarter flat y/i
domest revenu quarter flat y/i revenu
declin slightli y/i
declin due competit pressur categori declin eu
woundcar other
woundcar revenu quarter increas y/i
domest revenu woundcar quarter declin y/i
revenu increas y/i
increas due strong uptak band-aid new product launch
japan off-set lap prior year inventori build support trade
promot competit stock
world-wide pharmaceut revenu quarter
increas y/i compar growth led
strong perform oncolog continu growth immunolog
over-the-counter revenu
report
oper y/i
compar
woundcar
revenu quarter
increas y/i
revenu
woundcar
increas
revenu quarter
increas y/i
compar
compar
revenu
neurosci
quarter
increas
report
revenu
neurosci
quarter
increas
report
world-wide pharmaceut revenu increas
y/i compar world-wide oper result
exclud net impact acquisit divestitur driven new
product strength core product strong growth new product
includ darzalex imbruvica tremfya guselkumab treatment
adult live moder sever plaqu psoriasi
domest revenu increas revenu
increas reflect oper increas
posit currenc impact
domest revenu increas revenu
increas reflect oper increas
posit currenc impact
revenu immunolog quarter increas
report oper y/i compar
domest sale increas intern sale
increas y/i
growth driven strong uptak stelara crohn diseas
immunolog market growth launch tremfya strength across major
region simponi simponi aria
lower sale remicad due increas discounts/reb biosimilar
revenu infecti diseas increas report basi
quarter compar domest
sale declin y/i intern increas y/i
growth due strong sale prezcobix/rezolsta continu
success odefsey launch symtuza mostli off-set lower sale
olysio prezista
revenu neurosci quarter increas
y/i report basi compar domest
sale increas intern sale increas
world-wide paliperidon long-act inject grew strength invega
trinza/trevicta invega sustenna/xeplion partial off-set
cannib risperd consta gener competit
revenu oncolog quarter grew
y/i report basi compar
domest sale grew y/i intern sale grew
darzalex saw continu strong uptak eu especi prior line
set launch countri europ strong sale
imbruvica due increas patient uptak global higher market
share growth across multipl indic new total patient share
leader line cll line mcl strong sale zytiga
driven market growth latitud data strong growth also
seen japan eu
revenu
quarter
increas
report
sale
increas
report oper
increas
compar
increas
reflect
oper increas
posit
currenc impact
revenu cardiovascular/metabol quarter
increas y/i report basi compar
domest sale declin slightli y/i intern
sale went y/i
xarelto increas market share driven access win partial off-set
higher discount manag care/govern channel invokana/
invokamet lower sale mainli due increas contract discount
higher util medicaid share loss
total revenu quarter domest sale
intern sale sale led opsumit
tracleer uptravi
world-wide medic devic sale increas
y/i report basi compar growth
driven continu strong product perform vision
cardiovascular improv growth surgeri
world-wide medic devic sale increas
report compar world-wide sale driven
electrophysiolog product cardiovascular busi endocutt
biosurg advanc surgeri busi acuvu contact lens
vision busi wound closur product gener surgeri
busi partial off-set declin diabet busi spine
product orthopaed busi
revenu
cardiovascular
quarter
increas
report
revenu diabet
quarter
report
revenu
orthopaed
quarter flat
increas
reflect
oper increas
posit
currenc impact
domest sale increas intern sale
increas reflect oper increas
posit currenc impact
domest sale increas intern sale
increas reflect oper increas
posit currenc impact
revenu cardiovascular quarter
increas report oper domest sale
increas intern sale increas
revenu diabet
quarter
report
electrophysiolog saw growth primarili driven af procedur
growth continu uptak thermocool smarttouch contact
sens cathet partial off-set cordi divestitur transit
revenu
orthopaed
quarter
declin report
basi y/i compar
revenu diabet quarter declin
report oper domest sale decreas
intern sale decreas
declin due bgm price declin categori share
soft emea coupl pump discontinu canada
revenu orthopaed quarter declin
report basi y/i compar domest sale
intern revenu
hip saw continu uptak corail primari stem platform
leadership posit anterior approach knee impact
india implant price legisl trauma saw strength latin america
new product perform asia pacif coupl continu uptak
tfn-advanc nail system spine share loss
spine due portfolio gap
revenu surgeri quarter increas
y/i report basi compar domest
sale increas intern sale increas
revenu surgeri
quarter
increas y/i
report basi compar
advanc medicin endocutt driven minim
invas surgeri penetr china new product growth ou
competitor suppli issu emea
driven acquisit megadyn partial off-set
market share declin biosurgeri driven
market growth strength asia pacif latin america
revenu
visioncar quarter
increas
y/i report basi
compar
revenu visioncar quarter increas
y/i report basi compar domest
sale grew y/i intern sale increas y/i
contact lenses/oth categori consumpt growth driven new
product includ oasi day trade-up medic optic ceh
acquisit also result revenu growth surgic growth driven
strateg partnership collabor licens arrang
quarter number product compound develop
collabor strateg partner licens compani
remicad simponi/simponi aria market partner schering-
plough ireland compani subsidiari merck co inc mitsubishi
tanab pharma corpor tremfya guselkumab discov use
licens inc
olysio develop collabor medivir ab prezcobix/ rezolsta
fixed-dos combin symtuza odefsey develop
collabor inc juluca collabor viiv
licens mitsubishi tanab pharma corpor xarelto product
co-develop bayer healthcar ag procrit/eprex licens
imbruvica develop collabor co-market
pharmacycl llc compani zytiga licens btg
ltd velcad develop collabor millennium
takeda oncolog compani darzalex licens genmab a/
uptravi licens suppli agreement nippon shinyaku co-
promot japan opsumit co-promot agreement also
nippon shinyaku japan
monovisc/orthovisc licens inc
remicad
schering-plough
subsidiari merck
combin
licens mitsubishi
follow develop
 food drug
rilpivirin
dolutegravir first
drug regimen
treatment human
golimumab
treatment adult
activ psoriat arthriti
 food drug administr fda approv juluca rilpivirin
dolutegravir first complet single-pil two-drug regimen
treatment human immunodefici viru type infect
fda approv mg once-daili dose xarelto rivaroxaban
reduc continu risk recurr venou thromboembol
complet least six month initi anticoagul therapi
fda approv simponi aria golimumab treatment adult
activ psoriat arthriti activ ankylos spondyl
european commiss ec approv tremfya guselkumab
treatment adult moder sever plaqu psoriasi
ec approv broaden exist market author zytiga
abirateron acet plu prednison prednisolon includ treatment
newly-diagnos high-risk metastat hormone-sensit prostat cancer
regulatori applic submit fda european medicin
agenc expand current indic darzalex daratumumab use
combin bortezomib melphalan prednison treatment
newli diagnos patient multipl myeloma inelig autolog stem
submit fda
european medicin
agenc expand
current indic
supplement new drug applic submit fda two new
xarelto rivaroxaban vascular indic reduc risk major
cardiovascular cv event cv death heart attack stroke patient
chronic coronari and/or peripher arteri diseas cad/pad
reduc risk acut limb ischemia patient pad
world-wide collabor licens agreement complet legend
subsidiari genscript corpor develop manufactur
commerci chimer antigen receptor t-cell therapi l-
target bcma treatment multipl myeloma
divestitur
compe hra pharma
complet
alafenamid
treatment human
snda invokana
canagliflozin
submit fda
applic ema
includ data
consum icon brand unparallel consum insight
prioriti acceler growth prioriti categori across multipl channel
strategi focu critic geographi icon mega brand
plan growth
broaden scope innov model breakthrough global platform
drive insight-l innov deliv superior differenti product
medic devic comprehens portfolio acceler growth strategi
prioriti acceler growth innov partnership portfolio
manag new busi model
strategi strengthen foundat simplifi oper reshap busi
portfolio anticip respons major chang industri
plan growth
build world-class commerci capabl across portfolio
execut robot digit survey solut
integr holist insights-driven capabl help health system navig
pharmaceut industri lead pipelin commerci excel
prioriti drive continu growth deliv near term pipelin
strategi focu therapeut area high unmet medic need robust
innov commerci capabl
plan growth
expand profil key lifesav life chang product darzalex
imbruvica stelara
enabl best class uptak tremfya
secur regulatori approv apalutamid
submit nme line extens
revenu expect oper
revenu expect rang
effect tax rate expect
net interest expens expect around
adjust ep expect rang
expect ep growth y/i
pharmaceut
segment focu
therapeut area high
robust innov
revenu
expect
revenu expect
rang
adjust ep expect
rang
expect ep growth
y/i
continu consist growth exceed financi expect
strong sale growth seen across busi pharma segment lead
way double-digit growth adjust ep achiev high-singl digit
consum product segment flat growth partli driven beauti
franchis partli off-set babi product continu impact
new entrant market medic devic segment mid-singl digit
growth driven vision care cardiovascular franchis
actelion acquisit pulmonari hypertens strong start
oncolog darzalex grew surpass
sale darzalex continu increas market share line two
three experienc market growth line four
complet acquisit licens variou size
innov deal made new invest
flat growth
partli driven beauti
franchis partli off-set
babi product
continu impact
new entrant market
acquisit licens
deal made new
non- reconcili
non- reconcili
non- reconcili
incom statement
strateg partnership collabor licens
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
gross margin decreas ttm compar y/i
revenu growth increas ttm y/i
ep growth ttm compar y/i
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth johnson johnson| februari
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale johnson johnson| februari
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale johnson johnson| februari
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item johnson johnson| februari
balanc sheet item
outstand equival market properti plant properti plant issuanc prefer issuanc chang johnson johnson| februari
sinc jan seen signific increas price-to-earnings trade band
time surpass even reach almost due recent downfal
stock price litig face compani price-to-earnings around band
incom statement
strateg partnership collabor licens
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
breakdown share held insid share held institut mutual fund float held institut mutual fund institut hold direct holder form domin michael sandra gari ronald institut holdersholdershar report outvaluevanguard group inc state mutual automobil insur northern trust america wellington manag compani geod capit manag norg invest top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard institut fund-institut fidel ishar washington mutual investor select sector spdr fund-health vanguard -valu mf seri trust i-mf valu johnson johnson| februari
developmentsfda mini-sentinel assess confirm safeti effect xarelto rivaroxaban associ lower risk ischem stroke vs warfarinth janssen compani johnson johnson announc find food drug administr fda mini-sentinel assess confirm posit safeti efficaci profil xarelto rivaroxaban establish phase rocket af clinic trial publish pharmacoepidemiolog drug safeti landmark schizophrenia data bring break cycl hospit incer receiv fda approv inclus invega sustenna paliperidon palmit labeljanssen inc announc invega sustenna paliperidon palmit once-monthli schizophrenia treatment first antipsychot food drug administr fda approv inclus real-world data product label janssen enter world-wide collabor licens agreement chines compani legend develop investig -t anti-canc therapi dec janssen inc janssen janssen compani johnson johnson announc enter world-wide collabor licens agreement legend usa inc legend ireland limit legend subsidiari genscript corpor develop manufactur commerci chimer antigen receptor t-cell drug candid specif target b-cell matur antigen bcma fda grant prioriti review janssen apalutamid treatment non-metastat castration-resist prostat cancer dec janssen inc janssen announc food drug administr fda grant prioriti review design new drug applic nda apalutamid investig next-gener oral androgen receptor ar inhibitor treatment men non-metastat castration-resist prostat cancer current fda-approv treatment patient non-metastat januari johnson johnson| februari
incom statement
strateg partnership collabor licens
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
return
gross margin ttm
beat sector
industri
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit johnson johnson| februari
consensu view analyst trend stock
rate expect
forward price-to-earnings
jnj avgfive-year growth forecast usdgrowth high day day day estim comparisonjnjindustri avg avgprice/earn yield johnson johnson| februari
consensu view analyst trend stock
earn growth
estim respect
revenu growth
estim
adjust ep expect
estimatescurr analyst estimatethi estim estimatepast ep growthpeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last daysn/an/an/an/a current surprisescurr growth rate johnson johnson| februari
incom statement
strateg partnership collabor licens
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
stock price dip high feb weak result consum product
relat verdict face late jan
stock given neg return last month
stock shown signific rise price reach high jan
stock shown uptrend sinc dec given total return last year
stock dip oct rise sinc
stock reach all-tim high jan given return last year
strong top-lin growth segment grew doubl digit
medic devic segment fair mid-singl digit growth pulmonari hypertens franchis
grow rapid rate pharma segment maintain hold rate target price
estim adjust ep along forward look price-to-earnings
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
